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Abstract
Significant age- and experience-dependent remodelling of spinal and supraspinal neural networks occur, resulting in altered pain
responses in early life. In adults, endogenous opioid peptide and endocannabinoid (ECs) pain control systems exist which modify pain
responses, but the role they play in acute responses to pain and postnatal neurodevelopment is unknown. Here, we have studied the
changing role of the ECs in the brainstem nuclei essential for the control of nociception frombirth to adulthood in both rats and humans.
Using in vivo electrophysiology, we show that substantial functional changes occur in the effect of microinjection of ECs receptor
agonists and antagonists in the periaqueductal grey (PAG) and rostroventral medulla (RVM), both of which play central roles in the
supraspinal control of pain and the maintenance of chronic pain states in adulthood. We show that in immature PAG and RVM, the
orphan receptor, GPR55, is able to mediate profound analgesia which is absent in adults. We show that tissue levels of
endocannabinoid neurotransmitters, anandamide and 2-arachidonoylglycerol, within thePAGandRVMare developmentally regulated
(using mass spectrometry). The expression patterns and levels of ECs enzymes and receptors were assessed using quantitative PCR
and immunohistochemistry. In human brainstem, we show age-related alterations in the expression of key enzymes and receptors
involved in ECs function using PCR and in situ hybridisation. These data reveal that significant changes on ECs that to this point have
been unknown and which shed new light into the complex neurochemical changes that permit normal, mature responses to pain.
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1. Introduction
Pain in infancy is a clinical concern and has been recognised as
being suboptimally managed.58 Previous studies have shown that
pain processing in young mammals is immature: nocifensive
withdrawal thresholds are lower, and response magnitudes are
greater and longer lasting during early life.21 Normal adult
processing of noxious sensory inputs requires a constant balance
between synaptic excitation and inhibition within the
somatosensory pathway.16,56 Descending modulatory pathways,
specifically the spino-bulbo-spinal loop, plays a key role in
modulating spinally mediated nociceptive reflexes.48 The peria-
queductal grey (PAG) of the midbrain and nuclei within the
rostroventral medial medulla (RVM) are pivotal within this
loop,18,32,39,40,43 as they integrate pain-related activity from fore-
brain structures and bidirectionally modulate spinal cord dorsal
horn (DH) excitability accordingly.18 Functional nociceptive pro-
cessing requires a prolonged period of postnatal maturation, and
immature pain behaviours are partly explained by the predom-
inance of synaptic excitation over inhibition within the
DH.1,20,22,28,30,38,39,53 Opioidergic activity within the descending
pathway is one of the major neurotransmitter systems responsible
for endogenous pain control,2,3,43 and we and others have
previously shown that significant postnatal refinement occurs in
the opioidergic signalling system.30,39
Alongside the opioidergic pain modulatory system, a parallel
endocannabinoid (EC) signalling system exists.12,42,60 In adult
rodents, the administration of synthetic cannabinoid agonists into
the PAG is antinociceptive,19,34,42 and this effect is known to be
mediated via the CB1 cannabinoid receptor.12 The other
cannabinoid receptor, CB2, is mainly expressed by peripheral
immune cells.49 However, CB2 receptor is also expressed by
neurons and glial cells within the brainstem and DH, and upon
activation alleviates inflammatory pain hypersensitivity.14,25 Ad-
ditionally, a nonclassic cannabinoid receptor, GPR55, is
expressed by both neuronal and glial cells within the central
nervous system (CNS).45 The study of GPR55-mediated pain
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modulation is still in its infancy,24,52,54 and roles in both
pronociception and antinociception upon receptor activation
were observed.52
It is widely accepted that apart from pain modulation, the EC
signalling system serves a trophic role in utero, guiding neuronal
and glial migration, axon elongation, and synaptogenesis.27,51
More importantly, the role of the EC signalling system in
neurodevelopment and maturation continues after birth,23,37 as
prolonged exposure to the psychoactive cannabinoid of mari-
juana, D-9-tetrahydrocannabinol during adolescence causes
plastic changes in the hippocampus.47 Given the role of the EC
signalling system in pain modulation and neurodevelopment, we
sought to investigate the role of the EC system on postnatal
maturation of pain processing.
Here, we report significant age-dependent plasticity within the
supraspinal EC system that alters DH nociception. This article
maps these changes for the first time in both rodent and human
brains at a molecular and functional level. These data have
profound implications for our understanding of supraspinal
control of spinal nociception and the treatment of pain in early life.
2. Materials and methods
2.1. Animals
Postnatal day (P)3, 14, and 40, Sprague-Dawley rats were
purchased from Charles River, United Kingdom. These ages were
chosen for our study, as it spans across early to late postnatal
maturation of the rat, and pain behaviours reach maturity around
P40. Pups were housed with their dams in individually ventilated
cages in an in-house animal facility. Free access to food and water
was available throughout. All experiments were performed in P10,
P21, and P40 rats during the animals’ light cycle. Experimental
procedures were performed under the Home Office License
40/3647 and in accordance with the Animals (Scientific Proce-
dures) Act 1986 and IASP guidelines. Whilst we acknowledge that
this term is controversial and that rats at this age/weight are not fully
adult, they display many of the behavioural, physiological, and
anatomical responses seen in adults and are routinely used as
adults in the entire pain literature.
2.2. Surgery
Periaqueductal grey and RVM microinjection animals were
anaesthetised with isoflurane (Baxter, Newbury, Berkshire,
United Kingdom) and mounted on a stereotaxic frame (Kopf
Instruments, Tujunga, CA). The skull was exposed and the
bregma was located. Stereotaxic coordinates for the ventral PAG
(vPAG) and RVM were calculated (PAG: both P40 and P21:
left-right [L-R] 0.5 mm; anterior-posterior [A-P]27.8 mm; dorsal-
ventral [D-V] 26.0 mm; P10: L-R 0.5 mm; A-P 27.8 mm;
DV24.5 mm; L-R 0.5; A-P27.8 mm; D-V24.5 mm: RVM: P40:
L-R 0 mm; D-V 210 mm; A-P 29.7 mm; P21: L-R 0 mm; D-V
210 mm; A-P 29.2 mm; and P10: L-R 0 mm; D-V 28 mm; A-P
28.7 mm), and a 26-gauge 2.5-mL syringe (Hamilton, Reno, NV)
was inserted through a drilled hole in the skull. Drugs were
injected over a 5-minute period, after which the syringe was
removed and the wound was closed. Total volume of drug
administered into the PAG was 1 and 0.5 mL to the RVM at P21
andP40with 0.5mL (PAG) and 0.25mL (RVM) being administered
to P10 rats in accordance with previously published studies30,39;
only 1 drugwas administered per animal. Total brain volume is the
same between P21 and P40 (see Ref. 29), and therefore, the
same volume for injections was used.
2.3. Electromyographic recordings
Anaesthesia (isoflurane) in P21 and P40 rats was maintained with
a surgically implanted endotracheal cannula,whereas inP10 rats, it
was maintained with a fitted nose cone. Isoflurane concentration
was kept at 1.3% to maintain light anaesthesia, as previously
described.29,39 The fur overlying the biceps femoris muscle was
trimmed and a bipolar concentric needle electromyographic (EMG)
recording electrode (comprising a modified 27-gauge hypodermic
needle; Ainsworth, Coventry, United Kingdom) inserted into the
belly of the muscle. The EMG electrode was connected to
a NeuroLog head-stage (NL100AK; Digitimer, Welwyn Garden
City, United Kingdom), signals amplified 32000 (NL104A), band-
pass filtered between 10 and 1000 Hz (NL125) before being
sampled at 2 kHz using LabChart software via a PowerLab data
acquisition unit (AD Instruments Ltd, Oxford, United Kingdom). In
these experiments, spinal reflex excitability was determined by the
EMG activity of flexor hind limb muscle evoked by mechanical
stimulation of the plantar hind paw using von Frey hairs (vFh).
Responses to 2 subthreshold vFh (T 2 1 and T 2 2) and the
threshold hair (T) and a suprathreshold hair (T11)were recorded and
thesame4hairs used inall subsequent stimulationconditions for data
analysis. Thresholds were determined as the vFh that produced an
EMG responsemore than 10%greater than the resting EMG activity.
Each hair was then applied 3 times, and themean reading for each of
the 3 presentations recorded. Different hairs were used in each age
group as mechanical withdrawal thresholds increase with age. A
stimulus-response curve of EMGmagnitude vs mechanical stimulus
intensity was plotted, and the area under the curve was calculated to
provide an integrated measure of spinal reflex excitability. Specific
hairs used in each agewere (P10: 15, 26, 60, and 100g; P21: 26, 60,
100, and 180 g; and P40: 60, 100, 180, and 300 g).
2.4. Immunohistochemistry
P10, P21, and adult rats were overdosed with intraperitoneal (i.p.)
injection of sodium pentobarbital (P21 and adults, 2mL; P10, 1mL).
Animals were then transcardially perfused with 4% paraformalde-
hyde and brains quickly dissected. The PAG and the RVM were
sectioned (40 mm) on a freezing microtome (Leica, SM2010R).
Tissue was blocked with 3% serum with 0.3% triton X100
(SigmaAldrich, United Kingdom) for 1 hour before incubationwith
primary antibody. The primary antibodies used were goat anti-
CB1 (Frontier Institute, Tokyo, Japan, 1:20032). This antibody has
been validated previously in rat tissue. Sections were incubated
with this antibody overnight at room temperature. After incubation
with the primary antibody, sections were incubated with Alexa
Fluor–conjugated (Invitrogen, Loughborough, United Kingdom)
secondary antibodies (1:500) for 2 hours at room temperature.
Immunofluorescent sections were observed with a Leica IRE2
fluorescence microscope fitted with a Hamamatsu Orca-ER mono-
chrome camera and captured using Volocity 6.1 software (Perkin
Elmer, Llantrisant, United Kingdom). Same exposure time of image
acquisition was used for each sections staining for the different
antibodies from the different animals to ensure consistent brightness
in images. Image J1.29 (National Institutes ofHealth, Bethesda,MD)
was used to adjust brightness and contrast of the images
postacquisition. Systematic random sampling and unbiased ste-
reological methods were used for quantification semiquantitative
analysis as adopted from previously published studies.26,41
2.5. TaqMan real-time PCR
Human brain tissue was obtained from the Nottingham Biobank.
Ethical approval for this study was sought and granted (Study
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ACP0000100), and studies were conducted in Human Tissue
Act–registered (2004) laboratories. Tissue was selected to come
from cases aged 25 to 29 weeks of gestation, 38 to 39 weeks of
gestation, and older than 2 years. Cause of death was provided
and included transcervical ascending infection/foetal inflammatory
syndrome, uteroplacental perfusion deficiency (1 with concomitant
Streptococcus B infection), osteoskeletal dysplasia, multiple
congenital malformations, placental villous dysmaturity, or no
significant abnormality. Tissuewasprovidedasparaffin-embedded
blocks, including the midbrain, pons, and medulla. Real-time (RT)
PCRwas conducted on 10 mm sections from each block following
the same procedure as described below. Primers and probes for
the human sequences were designed in an analogous manner to
that stated below (in the paragraph after next).
P10, P21, and P40 rats were overdosed with i.p. injection of
sodium pentobarbital (P21 and P40s, 2 mL; P10, 1 mL). Their
brains were quickly dissected out on ice. Tissue from the PAG
and RVM was isolated. Samples were flash frozen in liquid
nitrogen and stored at 280˚C.
TaqMan quantitative RT-PCR was performed using the
StepOnePlus Real-Time PCR System (Applied Biosystems,
Forster City, CA). Primers and probes for glyceraldehyde
3-phosphate dehydrogenase (GAPDH; National Center for Bio-
technology Information [NCBI] reference sequence
NM_017008.3), CB1 receptor (NM_012874.4), CB2 receptor
(NC_005104.4), GPR55 receptor (XM_006245494.1), NAPE-
PLD (NM_199381.1), and DAGLa (NM_006133.2) were
designed on Primer Express 3 (Applied Biosystems). Each
sample was run in triplicates. Expression of target genes was
normalised to GAPDH, and expression of target genes was
determined using the relative standard curve method. All
sequences for primers were validated with a BLAST search.
2.6. Liquid chromatography–mass spectrometry analysis
of endocannabinoids
P10, 21, and 40 rats were killed by overdose of i.p. sodium
pentobarbital, and PAG and RVM tissue were dissected and
frozen in liquid nitrogen.
A liquid chromatography–mass spectrometry method was
used for analysis of ECs based on a previously published method
[69]. Internal standards of 100 mL of 2-arachidonoylglycerol
(2-AG)-d8 (10 mM) and 15 mL of AEA-d8 (28 mM) were added to
each tissue sample or EC standards and vortexed briefly. Ethyl
acetate: hexane (9: 1 vol/vol) was added to each sample, vortex
mixed (10 minutes), and centrifuged (13,000 rpm, 10 minutes,
4˚C). The procedure was repeated and the supernatants pooled
and evaporated using a vacuum centrifugal evaporator. Prior to
analysis, each sample extract was reconstituted in 100 mL of
acetonitrile. The injection volume was 10 mL. EC standards (AEA,
2-AG, oleoylethanolamine [OEA], and palmitoylethanolamine
[PEA] and internal standards 2-AG-d8 and AEA-d8) were
purchased from Axxora Laboratory services, Bingham, Notting-
ham, United Kingdom. The HPLC system used was a Shimadzu
SCL-10Avp (Shimadzu, Columbia, MD) coupled to a triple
quadrupole ion-trap 4000 QTRAP mass spectrometer (AB
SCIEX, Warrington, United Kingdom) equipped with Turbo
Spray ionisation interface. Analytes were separated chromato-
graphically on a Waters Symmetry C18 column (internal
diameter 100 3 2.1 mm, particle size 3.5 mm) with a mobile
phase flow rate of 0.3 mL/min. Multiple-reaction monitoring of
individual compounds using specific precursor and product
mass-to-charge (m/z) ratios allowed simultaneous measure-
ment of AEA, 2-AG, OEA, and PEA. Quantification was by the
internal standard method with extracted calibration standards,
and data analysis was performed using Analyst v 1.4.2 (AB
SCIEX).
2.7. Statistics
All individual data points were represented as mean 6 SEM.
Electromyographic data were normally distributed. Statistical
comparisons between the age groups and drugs were made
using 2-way analysis of variance (ANOVA) or 1-way ANOVA with
Bonferroni multiple comparisons. Statistical comparisons be-
tween the age groups for the expression of various endocanna-
binoid targets in mass spectrometry, TaqMan, and RT-PCR
experiments were made using 1-way ANOVA with Bonferroni
multiple comparisons.
3. Results
3.1. Expression of ECs is developmentally regulated in the
periaqueductal grey and rostroventral medulla
We first measured the concentrations of endogenous CB1
receptor ligands, anandamide (AEA) and 2-AG, in the PAG and
RVM of postnatal day (P)10, P21, and P40 rats by tandem
liquid chromatography–mass spectrometry. In the PAG (Fig.
1A) and RVM (Fig. 1B), the levels of AEA significantly
increased during the early postnatal period and reached
mature levels by P21. Similarly, 2-AG levels in the PAG (Fig.
1C) and RVM (Fig. 1D) also increased and reached mature
levels by P21. Consistent with previous reports, the measured
concentration of 2-AG is higher compared with anandamide in
the brain regions tested, as AEA is measured in pmol/g range,
whereas 2-AG in nmol/g range.8 Collectively, these data
indicate that the expression of ECs increases with postnatal
age of the rat.
Oleoylethanolamine and PEA were also measured (supple-
mental Fig. 1, available online at http://links.lww.com/PAIN/
A471). Although OEA and PEA lack affinity at CB1 and CB2
receptors,10 they exert similar effects as other synthetic
cannabinoids, via the peroxisome proliferator–activated
receptor-alpha, GPR55, and GPR119 receptors.12,55 There were
no changes in PEA levels in the PAG (supplemental Fig. 1A,
available online at http://links.lww.com/PAIN/A471), but PEA
levels in the RVM increased with postnatal age and were highest
in P40s (supplemental Fig. 1B, available online at http://links.lww.
com/PAIN/A471). The concentration of OEA in the PAG and RVM
also increased with postnatal age, and similarly, expression was
highest in P40s (supplemental Fig. 1C, D, available online at
http://links.lww.com/PAIN/A471).
We next assessedwhether the expression of endocannabinoid-
synthesising enzymes, N-acyl phosphatidylethanolamine–specific
phospholipase D (NAPE-PLD; synthesising anandamide) and
diacylglycerol lipase alpha (DAGLa; synthesising 2-AG), also
increases with postnatal age. In the PAG and RVM, we undertook
PCR investigations. We isolated mRNA from the ventrolateral PAG
(vPAG) (Fig. 1E) and the RVM (Fig. 1F) of P10, 21, and P40 rats.
We focused on the vPAG as neurons from this region indirectly
project to the DH via the RVM.3,59 The transcript levels of target
genes were normalised to the expression of GAPDH in the same
tissue, and quantification was performed using the relative
standard curve method.39
In the vPAG, NAPE-PLD mRNA transcript levels increased as
the rats aged, andNAPE-PLDmRNA transcript levels were higher
in P40s compared with P10 (Fig. 1E). No differences in DAGLa
mRNA transcript levels (Fig. 1E) were observed in the vPAG
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between the ages. In the RVM, no differences in DAGLa and
NAPE-PLD mRNA transcript levels were observed between the
ages (Fig. 1F).
To investigate whether our results are translational in humans,
we also measured mRNA levels of NAPE-PLD in the midbrain of
postmortem human tissue deposited in the Nottingham Biobank
by TaqMan qRT-PCR. Tissues were selected to span a range of
ages from subjects who were born preterm (24-26 weeks
postconceptional age, n 5 8), full term (39-40 weeks post-
conceptional age, n5 8), infants (3-8 months, n5 8), and adults
(14-60 years, n 5 4). mRNA levels were measured using
a geometric mean of reference genes (cyclophilin A and
hydroxymethylbilane synthase).We found that NAPE-PLDmRNA
transcript level was higher in infants than in both preterm and full
term (Fig. 1G), which suggests that like the rat, expression of EC-
synthesising enzymes undergoes significant postnatal modula-
tion during development in humans.
3.2. Expression of cannabinoid receptors also undergoes
significant postnatal refinement
Results from our previous experiments implied that the
expression of ECs within the brainstem nuclei is upregulated
as rats mature. Therefore, we sought to understand whether
there is also postnatal modification of EC receptors within these
brainstem nuclei. Expression of the CB1, CB2, and GPR55
receptors in the rat was examined using TaqMan RT-PCR. The
expression of CB1 and CB2 receptors in the human midbrain
was studied using TaqMan RT-PCR and in situ hybridisation
techniques.
In the rat PAG, CB1 mRNA transcript levels decreased with
age, but this trend did not reach statistical significance (Fig. 2A).
Immunohistochemistry demonstrated that CB1 staining was
mostly diffuse fibres (Fig. 2B), found at the axonal terminals,
consistent with previously published findings.60 CB1 immunore-
activity was particularly dense in the region immediately adjacent
Figure 1. Changes in the expression of endocannabinoids (eCBs) and eCB-synthesising enzymes in the brainstem nuclei of the rat and human midbrain during
postnatal development. (A and B) Mass spectrometry analysis of anandamide levels in the periaqueductal grey (PAG) and rostroventral medulla (RVM). Expression
of anandamide increased during early postnatal development and reached maturity by postnatal day (P)21. (P , 0.05 in the PAG and RVM; 1-way analysis of
variance [ANOVA].) (C andD)Mass spectrometry analysis of 2-arachidonoylglycerol (2-AG) levels in the PAG andRVM. No changes in the expression of 2-AGwere
observed in the PAG (C). Expression of 2-AG increased during early postnatal development and reachedmaturity by P21 in the RVM (D; P, 0.01; 1-way ANOVA).
(E) Taqman real-time (RT) PCR analysis of the eCB-synthesising enzymes NAPE-PLD and DAGLa in the ventral PAG. Expression of NAPE-PLD mRNA increased
during early postnatal development and reached maturity by P21 (P, 0.05; 1-way ANOVA). (F) Taqman RT-PCR analysis of NAPE-PLD and DAGLa in the RVM.
No significant changes were observed. (G) Expression of NAPE-PLD mRNA was highest in the human infant midbrain compared with all other age groups tested
(P , 0.01; 1-way ANOVA). Nine to 11 animals per age group used for mass spectrometry experiments. Three to 4 animals per age group for Taqman RT-PCR
and immunohistochemical experiments. Four to 8 human midbrain tissue per age group used for TaqMan RT-PCR. Data shown here represent mean 6 SEM.
* and ** 5 P , 0.05 and P , 0.01, respectively, between age comparisons, 1-way ANOVA with Bonferroni multiple comparisons.
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to the cerebral aqueduct. Staining intensity analysis showed that
CB1 receptor immunoreactivity decreased as the rats and was
highest at P10 (Fig. 2C). In the rat RVM, no age-related
differences in CB1 mRNA transcript levels were observed (Fig.
2D). However, using immunohistochemistry, we found significant
differences in the expression pattern of CB1 within the nucleus
raphe magnus, specifically during postnatal development.
Immunoreactivity for CB1 receptors increased during postnatal
development and reached adult levels by P21 (Figs. 2E and F).
No differences in CB2 receptor mRNA transcript levels were
observed in the vPAG between the ages (Fig. 3A). Similarly, we
found no changes in CB2 transcript levels in the RVM (Fig. 3B).
No changes in the GPR55 mRNA expression were observed in
the PAG (Fig. 3C), but significant postnatal refinement to the
expression of GPR55 mRNAwas detected in the RVMwith levels
transiently and significantly upregulated at P21 (Fig. 3D).
In the human midbrain, no changes in the expression of either
CB1 or CB2 receptor mRNA were observed (Figs. 4A and B). To
examine the pattern of mRNA expression in human tissue, in situ
hybridisation techniques were used to investigate the expression
of CB1 and CB2 receptors in the midbrain of human preterm, full
term, infants, and P40s (Figs. 4C–F). Counting of CB1-positive
cells revealed that the expression of CB1 receptors is lowest in
P40s comparedwith earlier ages (Figs. 4C andD). Therewere no
differences in the CB1 receptor mRNA expression between
preterm, full term, and infants. There were also no changes in the
expression of CB2 receptor protein between the age groups
tested (Figs. 4E and F).
These findings suggest that unlike the ECs and EC-
synthesising enzymes, the expression of CB1, CB2, and
GPR55 receptors within the PAG is not developmentally
regulated; however, within the RVM, GPR55 mRNA transcription
is increased for a short period around P21. Our results also show
that in the human midbrain, the expression of CB1 receptors
undergoes significant postnatal refinement and is highest during
early infancy and childhood.
3.3. CB1/CB2 receptors in the brainstem nuclei inhibit
nociceptive reflex in both P21 and P40 rodents
The functional significance of the developing EC signalling system
on nociceptive reflexes was investigated by pharmacologically
activating cannabinoid receptors within the brainstem nuclei in
lightly anaesthetised rats at different developmental time points.
Various synthetic cannabinoids were microinjected into either the
vPAG or the RVM of each rat, and EMG recordings were
performed before and after drug administration in the bicep
femoris muscle to assess withdrawal reflexes to mechanical
stimulation of the hind paw using calibrated vFh. In our first
experiment, WIN55212 (4 mg, CB1 and CB2 receptor agonists)
was microinjected into the PAG of postnatal day (P)21 and P40
rats, as previously experiments showed a functional switch
in descending pain modulation between these ages (supplemen-
tal Fig. 2, available online at http://links.lww.com/PAIN/
A471).29,30,39,53 Intra-PAG WIN55212 significantly reduced
spinal reflex excitability (supplemental Fig. 2C, available online
at http://links.lww.com/PAIN/A471) and increased mechanical
withdrawal thresholds (supplemental Fig. 2D, available online at
http://links.lww.com/PAIN/A471) in both P21 and P40 rats
compared with vehicle controls. The increase in mechanical
withdrawal threshold was significantly greater in P40 rats
than P21.
To further investigate the consequences of activating
cannabinoid receptors on nociceptive reflexes, HU210 (4 mg,
CB1 andCB2 receptor agonists) wasmicroinjected injected into
the vPAG or the RVM of P10, P21, and P40 rats (Fig. 5).
Periaqueductal grey microinjection of HU210 potently reduced
spinal reflex excitability compared with vehicle controls in all age
Figure 2. Changes in the expression of endocannabinoid receptors CB1, CB2, and GPR55 in the brainstem of the rat during postnatal maturation. (A) TaqMan
real-time (RT) PCR analysis of CB1 receptor mRNA in the ventral periaqueductal grey (vPAG) of P10, P21, and P40 rats, no statistically significant changes were
observed between the ages. (B) Fluorescent image (320 magnification) and quantification (C) of CB1 immunoreactivity in the vPAG. White arrows denote CB1-
specific terminal staining. The expression of CB1 receptors in the vPAG decreased as the animals aged, as immunoreactivity was highest at P10 (P , 0.0001;
1-way analysis of variance [ANOVA]). TaqMan RT-PCR analysis of CB1 receptors in the rostroventral medulla (RVM) of P10, P21, and P40 rats, no changes were
observed between the ages. (E) Fluorescent image (320 magnification) and quantification (F) of CB1 immunoreactivity in the RVM. White arrows denote CB1-
specific terminal staining. The expression of CB1 receptors in the RVM increased as the animals aged (P , 0.01-0.001; 1-way ANOVA) (C and D) N 5 3 to 5
animals per age group. CTR, control. Data shown here representmean6SEM. **, ***, and ****5P, 0.01,P, 0.001, and P, 0.0001, respectively, between age
comparisons, 1-way ANOVA with Bonferroni multiple comparisons.
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groups tested (Fig. 5A). A reduction in spinal reflex excitability was
accompanied by an increase in mechanical withdrawal threshold
(Fig. 5B). The same pattern was seen when HU210 was
microinjected in the RVM (Figs. 5C and D). Intra-PAG HU210-
induced antinociceptive effects were stronger in P21 and P40
animals compared with P10 (Figs. 5A and B), with the greatest
effect of HU210 being observed at P21 (Figs. 5C and D and
supplemental Figure 3; http://links.lww.com/PAIN/A471).
Collectively, these data showed that functional activation of
CB1 and CB2 receptors within the descending pain pathway is
antinociceptive throughout postnatal development. In addition,
some age-related differences were observed (increased efficacy
of HU210 at P21), which suggests that EC signalling via the CB1
and CB2 receptors undergoes significant refinement over the
early postnatal period.
3.4. Supraspinal GPR55 receptor–mediated analgesia in
early life
We next tested the effects of decreasing cannabinoid receptor
activity on nociceptive processing during postnatal maturation.
Intra-PAG microinjection of AM251 (2.77 and 1.35 mg, CB1
receptor inverse agonist) had no effect on spinal reflex excitability
in P40 rats compared with vehicle controls (Fig. 6A) and had no
effect on mechanical withdrawal threshold. However, intra-PAG
AM251 (2.77 mg) significantly inhibited spinal reflex excitability in
P10 and P21 rats. Mechanical withdrawal thresholds were
increased after intra-PAG AM251 in P21 rats only (Fig. 6B).
Similarly, intra-RVM AM251 (2.77 mg) significantly reduced spinal
reflex excitability and increased mechanical withdrawal thresh-
olds in P10 and P21 rats compared with vehicle controls (Figs.
6C and D). This result is surprising, as both agonist (HU210) and
inverse agonist (AM251) mediate the same effect on spinal
nociception in younger animals.
In addition to a role as a CB1 receptor inverse agonist, AM251
is also known to activate GPR55 receptors.33 Lysophosphatidy-
linositol (LPI) is known to be an endogenous agonist of this
receptor.44 Similar to the effect of AM251, intra-PAG microinjec-
tion of LPI (12 mg) significantly reduced spinal reflex excitability in
P10 and P21 rats compared with vehicle controls (Fig. 6A) and
significantly increased mechanical withdrawal thresholds in P21
rats (Fig. 6B). Intra-RVM LPI significantly reduced reflex
excitability in P10 and P21 rats compared with controls (Fig.
6C) and increasedmechanical withdrawal thresholds in both P10
and P21 rats (Fig. 6D). In P40 rats, neither intra-PAG nor intra-
RVM microinjection of LPI had an effect on mechanical
withdrawal thresholds, but intra-RVM LPI significantly increased
spinal reflex excitability when compared with vehicle controls.
To fully elucidate whether AM251 was acting via the GPR55
receptors and address the concern of using a higher dose (2.77
mg), we assessed the effects of low-dose (1.35 mg) AM251, on
spinal excitability in P21 and P40 rats when administered to the
vlPAG. Similar to our previous observations, low-dose AM251
(1.35 mg) had no effect in the P40 but reduced spinal reflex
excitability in P21 rats (Fig. 6E). Next, we tested the effect of
blocking GPR55 receptors in the vlPAG of P21 rats with the
GPR55 antagonist, ML193 (1 mg). Coadministration of ML193
with AM251 (1.35 mg) reversed the ability of AM251 to decrease
spinal excitability in P21 rats (Fig. 6E). Moreover, a significant
decrease in spinal reflex excitability was observed with both the
lower (1.35 mg) and higher doses (2.77 mg) compared with P21
animals receiving coadministration of AM251 and ML193. These
findings provided further support in the role of GPR55 on
antinociception via descending control systems early in life.
Figure 3. No changes in CB2 transcript levels in the periaqueductal grey (PAG) and rostroventral medulla (RVM) whilst the expression of the GPR55 gene is
developmentally regulated. (A and B) TaqManRT-PCR analysis oCB2 receptor mRNA in the PAG and RVM, respectively, no significant changes in were detected.
(C andD) TaqMan RT-PCR analysis of GPR55 receptor mRNA in the PAG and the RVMof P10, P21, and P40 rats (P, 0.001; 1way analysis of variance [ANOVA]).
No changes were observed in the PAG, but GPR55mRNAwas transiently upregulated at P21 in the RVM (D). N5 3 to 5 animals per age group. Data shown here
represent mean 6 SEM. ** 5 P , 0.01, between age comparisons, 1-way ANOVA with Bonferroni multiple comparisons.
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4. Discussion
Previous research has identified several postnatal modifications
within the pain pathway that affect on the development of
functional nociception. These include alterations in terminations
of primary afferent sensory neurons within the DH,6 immature
neuroimmune interactions,5 and a fundamental shift in supra-
spinal control over DH excitability, from predominantly excitatory
in early life to inhibition after the third postnatal week.29,53
As described elsewhere, the EC signalling system is essential for
normal brain maturation and pain processing.36 In our studies, we
report postnatal alternations in the expression of EC-related targets
in the midbrain of humans and the brainstem nuclei of rats, and
these changes have significant functional consequences on pain
modulation. Interestingly, our data also reveal a novel role for
GPR55 receptors in pain modulation during the early postnatal
period, as the expression of GPR55 receptormRNAwas highest in
the early adolescent period of the rat, and supraspinal activation of
GPR55 receptors strongly inhibited nociceptive reflexes in early
infancy and adolescence of the rat. Altogether, our research
provides further insights into our understanding in thematuration of
pain signalling systems during postnatal development.
4.1. Expression of endocannabinoids within the brainstem
nuclei during postnatal development
This is the first study of its kind tomeasure both the expression of EC
and EC targets within the brainstem nuclei in both rat and human
brains. Our major finding is that ECs in the rat PAG and RVM
Figure 4.Changes in the expression of endocannabinoid receptors CB1 and CB2 in the humanmidbrain during postnatal maturation. (A and B) TaqMan real-time
(RT) PCR analysis of CB1 and CB2 receptor mRNA, no significant changes in were detected. (C) In situ hybridisation images (320magnification) of CB1 receptors
in preterm, term, infant, and P40midbrain. (D) Quantification by cell-counting analysis showed that the expression of CB1 receptors is higher during early postnatal
development compared with P40 (P, 0.01; 1-way analysis of variance [ANOVA]). (E) In situ hybridisation images of CB2 receptors. (F) No significant changes in
the expression of CB2 receptors were observed throughout postnatal development. Four to 8 human midbrain tissue per age group was used for TaqMan
RT-PCR and in situ hybridisation, respectively. Data shown here represent mean 6 SEM. * and ** 5 P , 0.05 and P , 0.01, respectively, between age
comparison, 1-way ANOVA with Bonferroni multiple comparisons.
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increases with postnatal age. Liquid chromatography–mass spec-
trometry analysis showed significant increases in the levels of AEA in
both the PAG and the RVM; in parallel with this, the expression of
NAPE-PLD mRNA in the PAG increased as the animals aged and
reached maturity by the third postnatal week in the rat. In humans,
the expression of NAPE-PLD mRNA in the midbrain was highest in
infants compared with both preterm and full-term neonates.
Altogether, these findings suggest that the expression of AEA
increases within the brainstem nuclei of mammals during postnatal
development. Importantly, because of the nature of human tissuewe
obtained for this study, early life inflammation could also contribute to
changes in the expressionNAPE-PLDmRNA transcript levels during
infancy. Therefore, future experiments with a different cohort of
human tissue would provide further insight.
The levels of other ECs, such as 2-AG, also increase with
postnatal age in the RVM of the rat. In our study, only subtle
changes were detected in the expression of the 2-
AG–synthesising enzyme, DAGLa. No changes were detected
in the expression of DAGLa mRNA within the brainstem nuclei.
The disparity between DAGLa expression pattern and levels of 2-
AGmay be explained by the greater availability of the substrate for
the production of 2-AG or to age-related posttranslational
modifications; it has been shown that 2-AG can be synthesised
independently of DAGLa activity: PIP2 can be catalysed into 2-
arachidonoyl-lysophospholipid by phospholipase A1, which is in
turn hydrolysed by lyso-PLC to become 2-AG.46
4.2. Expression of cannabinoid receptors within the
brainstem nuclei during postnatal development
Wedid not find significant changes in the expression of either CB1 or
CB2 receptor mRNA with postnatal age, in both rats and humans.
However, in situ hybridisation experiments showed that the number
of CB1 receptor–positive cells in the human midbrain was highest
during infancy, and immunohistochemical expression of CB1
receptor underwent postnatal modification within the brainstem
nuclei of the rat. In linewith previous published findings,7,17 within the
rat PAG, CB1 receptor expression was found closely along the lining
of the aqueduct, and staining intensity decreased as the animals
aged.Wealso foundan increase inCB1 receptor immunoreactivity in
the RVM, The disparity between mRNA and immunohistochemical
data implies that changes in expression and function of the receptor
may reflect differences in the translation of mRNA rather than
changes in gene transcription. Additionally, it should be recognised
that immunohistochemically verified visualisation of receptor may, in
cases of fibre staining, reflect alterations in expression within cells in
other CNS centres that innervate the PAG or RVM. Nonetheless, the
expression of CB1 receptors at the protein level decreased in the
human midbrain and rat PAG with postnatal age.
GPR55 mRNA was detected in all the regions tested (Fig. 6). The
overall expressionwas lower comparedwith other endocannabinoid-
related targets.Within theRVM,GPR55mRNApeakedatP21,which
again echoes the theme that P21 is a critical time point when
developmentally regulated changes occur. In this study, immunohis-
tochemical localisation of GPR55 receptors was attempted but
because of technical reasons was unsuccessful. Validation of the
quantification of the mRNA levels of CB2 and GPR55 receptors was
attempted with immunohistochemistry as part of this wide-ranging
study. However, it was impossible for us to validate the specificity of
the antibodies against their respective targets, and therefore, these
data are not presented in this article.
4.3. Functional role of cannabinoid receptors in nociception
during postnatal development
In this study, we examined the role of cannabinoid receptors in the
brainstem on nociceptive processing during postnatal maturation.
We pharmacologically manipulated cannabinoid receptor activity by
Figure 5. Effect of intraperiaqueductal grey (PAG) and rostroventral medulla (RVM) microinjection of HU210 (CB1/2 receptor agonist, 4 mg/animal) on withdrawal
reflexes to mechanical von Frey hair stimulation in P10, P21, and P40 rats. (A) Intra-PAG HU210 significantly decreased spinal reflex excitability compared with
vehicle responses in all ages tested (P, 0.0001; 2-way analysis of variance [ANOVA]). This effect was more pronounced in P10 animals compared with P40s. (B)
Intra-PAG HU210 significantly increased mechanical thresholds in P21 and P40 rats (P, 0.0001; 2-way ANOVA). This effect is more pronounced in P21 and P40
animals compared with P10. (C) Intra-RVM HU210 decreased spinal reflex excitabilities compared with vehicle responses in all ages tested (P, 0.0001, 2-way
ANOVA). This effect was strongest in P21 animals. (D) Intra-RVM HU210 significantly increased mechanical thresholds compared with vehicle responses in all
ages tested (P , 0.0001, 2-way ANOVA). This effect was strongest for P21 animals. Four to 8 animals per drug per age group. Data shown here represent the
mean 6 SEM. **** 5 P , 0.0001, between drug comparisons, 2-way ANOVA with Bonferroni multiple comparisons. # and #### 5 P , 0.05 and P , 0.0001,
respectively, between age comparison, 2-way ANOVA with Bonferroni multiple comparisons.
November 2017·Volume 158·Number 11 www.painjournalonline.com 2229
in vivo intracerebral microinjections. Whilst we specifically targeted
the vlPAG and RVM, there is a slight possibility that the drugs we
administered could potentially diffuse into neighbouring regions
within the brainstem. Nonetheless, we showed that activation of
CB1/2 receptors in the brainstem regions at any of the ages tested
was always inhibitory. Initially, WIN55212 was injected into the PAG
ofP21 andP40 rats,whichwas antinociceptive in both ages.HU210
was used in subsequent experiments as a CB1/CB2 agonist
becauseHU210 is approximately a 100-foldmore potent at theCB1
receptors than WIN55212 (Ki for CB1 receptors, HU210 5 0.061
nM, WIN55212 5 62.3 nM). Application of HU210 in the PAG and
the RVM also reduced nociceptive behaviours in all ages tested,
further indicating that CB1/CB2 agonism is analgesic throughout
postnatal development.
These findings imply that although the expression of components
of the ECs changes with postnatal age, EC-dependent nociceptive
processing within the descending pathway via CB1 and CB2
receptors is not developmentally regulated. This is in line with
observations fromprevious studies,where systematic administration
of CB1/CB2 agonists, including WIN55212, CP55940, and HU210
inhibited nociceptive responses in young and adult rats.9,19,35,50
More importantly, it is known that the opioid and cannabinoid
signalling system work synergistically within pain modulatory path-
ways.11,13,61 Given that (1) significant postnatal refinement occurs
within opioid-mediated pain modulation pathway,30,39 and (2) ECs
play a trophic role in development, it is likely that the increase in ECs
contributes to maturation of opioid signalling during the postnatal
period, and this possibility warrants further investigation.
We also demonstrate an exciting new cannabinoid target for the
treatment of pain in early life.Changes in thephysiological functionsof
EC signalling system were revealed when we activate GPR55
receptors, by microinjecting LPI into the PAG and the RVM. Notably,
intra-PAG or RVM administration of LPI reduced spinal reflex
excitability and increased mechanical withdrawal thresholds in P10
and P21 rats, whereas in P40s, a mild increase in spinal reflex
excitability was observed after intra-RVM microinjection of LPI. The
effect of LPI onP40spinal reflex excitability reported inour study is line
with observations in other studies. We further substantiated the age-
dependent role ofGPR55-mediated signalling in thePAGbyblocking
the ability of AM251 to produce decreased spinal excitability in P21
ratswith the specificGPR55 receptor antagonistML193. Thegeneral
consensus is that GPR55 receptor–mediated activity is most likely to
be pronociceptive in mature animals.15 The receptor in the mature
CNS is coupled to the Gq proteins and when activated causes an
increase in intracellular calcium levels and synaptic excitability,15,57
whereas CB1 activation negatively couples to adenylate cyclase
activity via Gi proteins. It has also been shown that intraplantar
injection of LPI (2 pmol) leads to allodynia in P40 mice.24
Nonetheless, results from this study indicated that LPI in P40
RVMwas pronociceptive, whereas that in the immature PAG and
RVM was antinociceptive, which suggests a switch in GPR55-
mediated actions throughout postnatal development. Recently, it
Figure 6. Effect of intraperiaqueductal grey (PAG) and rostroventral medulla (RVM) microinjection of AM251 (CB1 receptor inverse agonist, GPR55 receptor agonist,
2.77 and1.35mg/animal) and lysophosphatidylinositol (LPI) (endogenousGPR55agonist, 12mg/animal) onwithdrawal reflexes tomechanical vonFrey hair stimulation
in P10, P21, andP40 rats. (A) Intra-PAGAM251 and LPI only decreased spinal reflex excitability in P10 andP21 rats (P, 0.0001, 2-way analysis of variance [ANOVA]).
There are significant age-related differences in AM251 and LPI responses between P40 and younger animals (P, 0.0001, 2-way ANOVA). (B) Intra-PAG AM251 and
LPI did not change the mechanical thresholds in either P10 or P40 rats, but significantly increased it in P21 animals. There are significantly age-related differences in
AM251 and LPI-mediated changes in mechanical withdrawal thresholds (P , 0.001, 2-way ANOVA). (C) Intra-RVM AM251 did not have an effect in P40 rats, but
significantly reduced spinal reflex excitabilities in P10 and P21 animals. Lysophosphatidylinositol increased spinal reflex excitability in P40 rats, but decreased it in P10
and P21 animals. These age-related differences were significant (P , 0.0001, 2-way ANOVA). (D) Intra-RVM AM251 and LPI significantly increased mechanical
thresholds in P10 and P21 rats, but had no effect in P40 animals. This age-related difference was significant (P, 0.0001, 2-way ANOVA). (E) Intra-PAG AM251 (2.77
and 1.35 mg) did not have an effect in P40, but significantly inhibited spinal reflex excitability in P21 animals (P, 0.0001, 1-way ANOVA). Coadministration of AM251
(1.35mg) with the GPR55 receptor–specific antagonist ML193 (1mg) reversed AM251-mediated inhibition of spinal reflex excitability in P21 animals. **, ***, and ****5
P, 0.01, P, 0.001, and P, 0.0001, respectively, between drug comparisons, 2-way ANOVA and 1-way ANOVAwith Bonferroni multiple comparisons. #, ### and
####5 P , 0.05, P , 0.001 and P , 0.0001, respectively, between age comparison, 2-way ANOVA and 1-way ANOVA with Bonferroni multiple comparisons.
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has been shown that GPR55 expressed on primary afferent
nociceptors is activated by lyso-phosphatidyl-b-D-glucoside,
released from spinal radial glia.27 This interactionwas essential for
the maturation of spinal nociceptive circuits, as disruption of it led
to misallocation of nociceptive axons into proprioceptive zones in
the DH. Supraspinal GPR55 receptors may also have a similar
neurodevelopmental role, and this warrants further investigation.
4.4. Role of the EC signalling system in maturation of pain
processing during the postnatal period
In summary, our data imply that the EC signalling system is
a promising target for pain management in immature patients.
Activation of CB1 and CB2 receptors in the brainstem nuclei is
always antinociceptive, regardless of postnatal age. In addition,
activation of supraspinal GPR55 receptors is only antinociceptive
in young animals, revealing fundamental development in the
physiological functions of the EC signalling system during
postnatal development, and GPR55 receptors as a novel target
for paediatric analgesic.
Concurrent with the postnatal development of the physiolog-
ical functions of the EC signalling system, anatomical studies
imply that the expression of ECs within the brainstem nuclei
increases with postnatal age. This anatomical refinement may be
important for endogenous pain inhibition throughout the post-
natal period, and mediating the maturation of synaptic con-
nections within the pain signalling pathway.
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